AstraZeneca and Merck rapidly advance LYNPARZA® (olaparib) in Japan
AstraZeneca and Merck announced they have submitted a NDA to Japan’s PMDA for the use of LYNPARZA® (olaparib) tablets in unresectable or recurrent BRCA-mutated breast cancer, with a decision expected in the second half of 2018. October 23, 2017